Core Insights - Vera Bradley, Inc. reported third quarter revenues of $62.3 million, a decrease from $70.5 million in the same period last year, indicating ongoing challenges in the market [4][5] - The company is implementing a transformation strategy called Project Sunshine, focusing on brand optimization and operational excellence [2][3] - Despite a net loss of $12.4 million for the third quarter, the company noted improvements in direct segment sales and a positive response to the return of iconic product styles [3][4] Financial Performance Summary - **Third Quarter Results**: Consolidated net revenues were $62.3 million, down from $70.5 million year-over-year. The net loss from continuing operations was $12.4 million, or $0.44 per diluted share, impacted by a $5.9 million inventory write-down and a $4 million media credit write-off [4][6] - **Nine Month Results**: For the nine months ended November 1, 2025, net revenues totaled $184.8 million, down from $232.4 million in the prior year. The net loss from continuing operations was $35.3 million, or $1.26 per diluted share [5][6] Segment Performance - **Direct Segment**: Revenues decreased by 5.3% to $49.7 million compared to $52.5 million in the prior year. Comparable sales declined by 5.8%, primarily due to reduced traffic in outlet channels [8][10] - **Indirect Segment**: Revenues fell by 30.2% to $12.6 million from $18.0 million in the previous year, attributed to a decline in specialty and key account orders [9][15] Gross Profit and Expenses - **Gross Profit**: Totaled $26.2 million, representing 42.1% of net revenues, down from 54.5% in the prior year, primarily due to inventory write-downs and increased duty expenses [10][16] - **SG&A Expenses**: Totaled $38.7 million, or 62.1% of net revenues, compared to 66.3% in the prior year, reflecting cost reduction initiatives [11][17] Operating Loss - The operating loss from continuing operations for the third quarter was $12.2 million, or 19.6% of net revenues, compared to a loss of $8.2 million, or 11.6% of net revenues, in the prior year [12][18] Balance Sheet Highlights - Cash and cash equivalents as of November 1, 2025, were $10.7 million, down from $12.3 million at the end of the previous year's third quarter. Total inventory decreased to $82.9 million from $109.6 million [20][21] Strategic Initiatives - Project Sunshine aims to enhance brand focus, improve digital capabilities, and optimize operational processes, with early signs of success noted in sales performance [2][3]

Group 1 - The company is evolving its business model to focus on acquiring and operating AI-driven software and network infrastructure companies in Southeast Asia, Europe, and North America [1] - Society Pass aims to invest in and acquire equity stakes in data center and telecom operators to strengthen its market position in the next generation e-commerce ecosystem in Southeast Asia [1] - The CEO highlighted the successful listing of NusaTrip Incorporated, which was acquired for under US$5 million and recently listed on Nasdaq with a market capitalization exceeding US$70 million, showcasing the company's ability to create shareholder value [2] Group 2 - Society Pass was founded in 2018 and operates in fast-growing markets such as Vietnam, Indonesia, Philippines, Singapore, and Thailand, which together represent over 80% of the Southeast Asian population [3] - The company operates three interconnected verticals: digital media, travel, and lifestyle, leveraging technology to enhance customer experience and transform the retail value chain in Southeast Asia [3] - Society Pass completed its initial public offering in November 2021 and began trading on Nasdaq under the ticker SOPA [4]

Core Insights - Innventure, Inc. has been added to the Russell 2000® Index and the Russell 3000® Index, effective December 22, 2025, as part of the annual reconstitution [1][2] - The inclusion in these indexes is expected to enhance the company's visibility within the investment community and broaden its shareholder base [2] Company Overview - Innventure is an industrial growth conglomerate focused on building companies with billion-dollar valuations by commercializing breakthrough technology solutions [3] - The company aims to bridge the "Valley of Death" between corporate innovation and commercialization through value-driven partnerships, operational experience, and capital-intensive scale-up expertise [3] Index Information - Membership in the Russell indexes is determined primarily by market capitalization and style attributes, and it remains in place for one year, updated annually [2] - FTSE Russell, which manages these indexes, is a global leader in providing benchmarking and analytics solutions, with approximately $18.1 trillion benchmarked to its indexes [4]

Vancouver, B.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Walker River Resources Corp. (“Walker” or the “Company”) (TSX-V: WRR) is pleased to announce additional assay results from the ongoing reverse circulation (“RC”) drill program at the Lapon Canyon portion of the Lapon Gold Project, located within Nevada’s Prolific Walker Lane Gold trend, 60 km SE of Yerington, NV. Highlights: Results from drilling on the new upper drill roads continue to confirm and extend gold mineralization to the south and the east of the ...

“Precision matters more than ever,” says fixed income ETF provider; points to opportunities in private credit, BB and CCC corporates, intermediate Treasuries and moreLARKSPUR, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BondBloxx Investment Management, a provider of precision fixed income ETFs with over $6 billion in assets, today released its 2026 Fixed Income Market Outlook providing advisors and investors with insights and investment ideas for the year ahead. “With uncertainty and market volatility expecte ...

Core Viewpoint - The American Hotel Income Properties REIT LP (AHIP) has appointed co-founder John O'Neill as the new Chief Executive Officer following the resignation of Jonathan Korol, with a focus on driving value for unitholders and maintaining operational excellence [1][2]. Company Overview - AHIP is a limited partnership that invests in hotel real estate properties across the United States, focusing on premium branded, select-service hotels located in secondary metropolitan markets [3]. - The company operates hotels under brands affiliated with Marriott, Hilton, and IHG Hotels through license agreements [3]. - AHIP's long-term objectives include increasing the value of its hotel properties through operational excellence, active asset management, and capital expenditures, as well as enhancing unitholder value and distributions [3]. Leadership Transition - John O'Neill's appointment is seen as a seamless transition due to his history with AHIP as a co-founder and previous CEO [2]. - The Board of Directors expressed gratitude towards Jonathan Korol for his leadership and wished him success in future endeavors [2]. Future Outlook - The company aims to focus on driving value for unitholders and is positioned strongly to move forward [2].

Core Insights - Praxis Precision Medicines has successfully completed discussions with the FDA, confirming the path to file a New Drug Application (NDA) for relutrigine in early 2026 [1][2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly those related to neuronal excitation-inhibition imbalance [4] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [4] Product Development - Relutrigine is a first-in-class small molecule aimed at treating developmental and epileptic encephalopathies (DEEs) by inhibiting persistent sodium current, which is a key factor in seizure symptoms [3] - In vivo studies have shown that relutrigine can achieve dose-dependent inhibition of seizures, with complete control observed in certain mouse models [3] - The EMBOLD study demonstrated a well-tolerated safety profile for relutrigine, with significant improvements in motor seizures among heavily pre-treated patients [3] Regulatory Designations - Relutrigine has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA for SCN2A-DEE, SCN8A-DEE, and Dravet syndrome, as well as Breakthrough Therapy Designation (BTD) from the European Medicines Agency [3]

GREENWICH, Conn., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (the “Company,” “we,” or “our”) today announced the following net asset value (“NAV”) estimate as of November 30, 2025. Management’s unaudited estimate of the range of the NAV per share of our common stock as of November 30, 2025, is between $16.34 and $16.64. This estimate is not a compreh ...

Core Insights - Premier Air Charter Holdings Inc. has announced the strategic addition of a Challenger 604 to its fleet, enhancing its charter capacity and reinforcing its growth trajectory in response to rising demand for business aviation [1][3] - The acquisition is part of a disciplined investment strategy aimed at strengthening market presence and driving long-term shareholder value [1][3] Company Strategy - The addition of the Challenger 604 is a significant milestone in Premier Air Charter's growth strategy, increasing charter capacity and enabling the company to meet rising demand in both business and leisure aviation markets [3] - The company aims to expand its footprint along the Eastern Seaboard, a region experiencing substantial growth, positioning itself to capture new opportunities and strengthen market presence [3] Operational Focus - Premier Air Charter continues to execute its vision of becoming a leading provider in the private aviation sector, reflecting a disciplined approach to growth and a commitment to operational excellence [3] - The company emphasizes reliability, innovation, and sustainability in its operations, aiming to exceed client expectations and foster lasting relationships [4]

Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholders and improve its financial d ...